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INTRODUCTION
Ovarian cancer is the most common cause of cancer death
from gynecologic malignancy. However, it is rarely diag-
nosed in early stage because of the insidious growth pattern
of this tumor. The management of ovarian cancer is surgery
and adjuvant chemotherapy. Ovarian cancer is often initially
responsive to chemotherapy but ultimately becomes refractory.
There have been some efforts in molecular biology to under-
stand chemotherapy resistance of ovarian carcinomas. In some
ovarian cancers, overexpression of several genes, including
HER-2/neu, myc, ras and p53 have been described (1). 
The c-kit proto-oncogene encodes a tyrosine kinase recep-
tor for stem cell factor, KIT, which is expressed in various
normal and tumor tissues (2, 3). Most of the c-kit mutations
have been described in gastrointestinal stromal tumors (GIST)
(4). Recent studies have shown that several tumors express
c-kit, such as lung (5), breast (6) and testicular (7) malig-
nancies. Coexpression of Kit ligand and c-kit has been report-
ed in gynecological tumors including serous adenocarcino-
mas and germ cell tumors of the ovary (8, 9). 
However, mutational analysis of c-kit in ovarian carcino-
ma has rarely been published. Immunohistochemistry for
the CD117 antigenic epitope identifies the KIT protein pro-
duct (a tyrosine kinase receptor) of the c-kit protooncogene
whose locus is present on chromosome 4q11-q12 (2). Muta-
tions of c-kit cause constitutive activation of this receptor,
which has been the target of the tyrosine kinase inhibitor,
imatinib mesylate (10). The most common mutations of the
c-kit protooncogene are exon 11 and exon 17 (11). Imatinib
mesylate blocks signal transduction in the presence of an exon
11-activating mutation, not exon 17 (12). To determine
whether treatment with imatinib mesylate might be useful
in ovarian tumors, mutational analysis is essential. The pur-
pose of our study is to determine if the ovarian epithelial car-
cinomas express KIT protein and to define mutational status.
MATERIALS AND METHODS 
Materials 
The archival materials are 43 cases of ovarian surface epithe-
lial tumors, which are 39 patients collected from the files
Pathology Department of Kyungpook National University
Hospital and 4 cases from Daegu Fatima hospital from 2000
to 2004. The 43 patients are consisted of 26 cases of carci-
nomas, 7 cases of borderline tumors, and 10 cases of benign
tumors. All the patients with carcinomas and borderline
tumors underwent abdominal hysterectomy with unilateral
or bilateral salpingo-oophorectomy. The hematoxylin-eosin
stained slides were reviewed and one block per case represen-
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Expression and Mutational Analysis of c-kit in Ovarian Surface
Epithelial Tumors 
Coexpression of Kit ligand and c-kit has been reported in some gynecologic tumors.
To determine whether imatinib mesylate is useful in ovarian epithelial tumors, we
performed immunohistochemical and mutational analysis. The cases consisted of
33 cases, which included 13 serous cystadenocarcinomas, 1 borderline serous
tumor, 8 mucinous cystadenocarcinomas, 6 borderline mucinous tumors and 5 clear
cell carcinomas. Five cases of serous cystadenoma and 5 cases of mucinous cys-
tadenoma were also included. In the immunohistochemical study, 3 cases (3/6, 50%)
of borderline mucinous cystic tumor and two cases (2/8, 25%) of mucinous cystade-
nocarcinoma show positive staining for KIT protein. Only one case (1/13, 7.7%) of
serous cystadenocarcinoma had positive staining. On mutational analysis, no muta-
tion was identified at exon 11. However, two cases of borderline mucinous tumors
and one case of mucinous cystadenocarcinoma had mutations at exon 17. In these
cases, the immunohistochemistry also shows focal positive staining at epithelial
component. Although, KIT protein expression showed higher incidence in mucinous
tumors than serous tumors, they lack KIT-activating mutations in exon 11. Thus,
ovarian surface epithelial tumors are unlikely to respond to imatinib mesylate.
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tative for the tumor was selected for immunohistochemistry
and mutational analysis. The clinical informations was based
on the patient’s medical records. 
Immunohistochemical analysis 
Five  m of formalin-fixed paraffin-embedded tissue sec-
tions were cut and immunostained with polyclonal rabbit
antibody c-kit (A4502, Dako, Carpinteria, CA, U.S.A.). Each
section was deparaffinized using xylene and subsequent hydra-
tion. The immunohistochemical studies were performed
using the streptavidine-biotin-peroxidase (Ultra Vision Kit;
LAB vision, Fremont, CA, U.S.A.) with diaminobenzidine
(DAB) as chromogen and Mayers’ hematoxylin as nuclear
counterstain. The assays were performed on an automated
stainer (BenchMark model; Ventana, Tucson, AZ, U.S.A.).
Sections of GIST were used as positive control. The intensity
of the immunostaining was graded as negative (no staining),
1+ (weak), 2+ (moderate), or 3+ (strong). Tumors staining
in greater than 10% of the tumor cells were considered to
be positive. 
DNA isolation, polymerase chain reaction (PCR), and sin-
gle-strand conformational polymorphism analysis (SSCP) 
From formalin-fixed paraffin-embedded tissue samples,
we cut 10- m thick sections from each sample. Genomic
DNA was extracted using QIAamp DNA mini kit (Qiagen,
Germany). Exons 11 and 17 of c-kit gene were amplified by
PCR using primers described in Table 1. Each PCR reaction
was performed in 20  L of reaction volume: 200 ng of genomic
DNA, commercial Perkin-Elmer (PE) buffer (1×10 mM
Tris-HCl, pH 8.4; 50 mM KCl), 1.5 mM MgCl2, 200  M
of each triphosphodeoxy-nucleotides (dNTP), one unit of
AmpliTaq Gold (PE) polymerase, and 0.1  M of each primers.
In the case of exon 11, the reaction mixture was denatured
at 94℃ for 3 min and subjected to 40 polymerization cycles
(94℃ for 30 sec, 51℃ for 30 sec, and 72℃ for 60 sec). In
the case of exon 17, the reaction mixture was denatured at
94℃ for 5 min and subjected to 40 polymerization cycles
(94℃for 30 sec, 51℃for 30 sec, and 72℃for 30 sec). PCR
reaction was run in GeneAmp 9600 thermocycler (PE). 
PCR-SSCP analysis for exon 11 and 17 were performed
in all cases. For SSCP analysis, each PCR product was mixed
with an equal volume of loading buffer (95% formamide,
0.05% bromophenol blue, and 0.05% xylene cyanol). After
denaturation at 94℃ for 5 min and snap cooling on ice, 3
L of each sample was loaded on polyacrylamide gels and
subjected to electrophoresis. For the analysis of exon 11, 10%
polyacrylamide gel was used and 8% gel was used for exon
17. The gels were stained using Silver Stain Plus kit (Bio-
Rad, Hercules, CA, U.S.A.), according to the manufactur-
er’s recommendation. 
RESULTS
Clinical data 
The 33 cases included 13 serous cystadenocarcinomas, 1
borderline serous tumor, 8 mucinous cystadenocarcinomas,
6 borderline mucinous tumors and 5 clear cell carcinomas.
To compare with the benign counterparts, 5 cases of serous
cystadenoma and 5 cases of mucinous cystadenoma were
Exon
PCR
product
Primer sequence
Exon 11 174 bp forward 5′ -GATCTATTTTTCCCTTTCTC-3′
reverse 5′ -AGCCCCTGTTTCATACTGAC-3′
Exon 17 174 bp forward 5′ -TCCTCCAACCTAATAGTGTATT-
CACAG-3′
reverse 5′ -TTTGCAGGACTGTCAAGCAGA-
GAATC-3′
Table 1. Primer sequences to detect c-kit mutations 
Fig. 1. Case No. 6. The c-kit immunohistochemical focal positive
staining in borderline mucinous tumor (×400).
Fig. 2. Case No. 23. The c-kit immunohistochemical positive stain-
ing in serous cystadenocarcinoma (×400).c-kit in Ovarian Surface Epithelial Tumors  83
included in the study. The mean age was 43.3 yr (range 20
to 76 yr). The stages of the carcinomas were as follows: Stage
I 11 cases, Stage II 3 cases, Stage III 12 cases. All the patients
with carcinomas and borderline tumors underwent total hys-
terectomy with unilateral or bilateral salpingo-oophorectomy.
The serous cystadenocarcinoma patients underwent omen-
tectomy and appendectomy with careful examination of all
serosal surfaces and biopsies of any suspected lesions. Ten
cases of serous cystadenocarciomas had omental or pelvic meta-
stasis of tumor cells. After surgery, a postoperative chemother-
apy was performed in mucinous and serous cystadenocarci-
noma, and clear cell carcinoma patients except two patients.
Fig. 3. Case No. 1, No. 6. Two cases of mucinous borderline tumors
had mutation at c-kit exon 17. M, markers; N, normal.
M1 3 5 6 N
Fig. 4. Case No. 14. One case of mucinous cystadenocarcinoma
had mutation at c-kit exon 17. M, markers; N, normal.
M2 31 4 N
Case 
No.
Age (yr) Laterality Stage Grade Diagnosis Follow-up c-kit IH Tumor sizes
(cm)
Exon17
mutation
1 21 13 Left Borderline M. tumor 2+ +
2 20 7 Left Borderline M. tumor - -
3 68 17 Right Borderline M. tumor - -
4 27 10 Right Borderline M. tumor 1+ -
5 29 30 Left Borderline M. tumor - -
6 22 16 Left Borderline M. tumor 2+ +
7 55 10 Both IIIb 1 M. cystadenoCa. - -
8 48 12 Right Ic 1 M. cystadenoCa. - -
9 23 24 Left Ia 1 M. cystadenoCa. - -
10 50 17 Left Ic 1 M. cystadenoCa. - -
11 20 14 Left c 2 M. cystadenoCa. - -
12 76 17 Left II 1 M. cystadenoCa. 1+ -
13 25 15 Left Ia 1 M. cystadenoCa. - -
14 20 18 Right Ic 1 M. cystadenoCa. 1+ +
15 37 10 NI Borderline S. tumor - -
16 50 14 Both IIIc 1 S. cystadenoCa. - -
17 60 8 Both IIIc 1 S. cystadenoCa. Recurred - -
18 49 6 Both IIIc 2 S. cystadenoCa. - -
19 40 11 Both IIb 2 S. cystadenoCa. - -
20 70 13 NI IIIc 2 S. cystadenoCa. Recurred - -
21 61 7 Both IIIc 2 S. cystadenoCa. - -
22 58 8 Left IIIc 3 S. cystadenoCa. - -
23 45 12 Right IIIc 2 S. cystadenoCa. 2+ -
24 60 12 Right Ic 1 S. cystadenoCa. - -
25 51 10 Left IIIc 3 S. cystadenoCa. - -
26 64 50 mL Left IIIc 3 S. cystadenoCa. - -
27 42 7 Both Ic 3 S. cystadenoCa. - -
28 54 11 Both IIc 2 S. cystadenoCa. - -
29 43 14 Left Ia 1 Clear cell Ca. - -
30 34 3.5 Left Ia 1 Clear cell Ca. - -
31 54 12 Both IIIc 1 Clear cell Ca. - -
32 47 10.5 Right Ia 2 Clear cell Ca. - -
33 64 8 Both IIIc 2 Clear cell Ca. Recurred - -
Table 2. The clinical data and results of immunohistochemistry and molecular study for c-kit in borderline and malignant ovarian tumors
NI, not informative; IH, immunohistochemistry; M., mucinous; S., serous; Ca, carcinoma; 1+, weak positive; 2+, moderate positive.84 D.-J. Kim, M.-H. Lee, T.-I. Park, et al.
One patient was stage Ia mucinous cystadenocarcinoma and
the other was stage Ia clear cell carcinoma. The chemothera-
py cycles were 6 to 12 cycles, consisted of cisplatin, cyclophos-
phamide and taxol. Two patients of serous cystadenocarcino-
ma and one patient of clear cell carcinoma recurred, but all
patients are still alive.
Immunohistochemistry 
Three cases (3/6, 50%) of borderline mucinous cystic tumors
and two cases (2/8, 25%) of mucinous cystadenocarcinomas
showed positive cytoplasmic staining for KIT protein (Fig. 1).
Only one case (1/13, 7.7%) of serous cystadenocarcinoma
had positive staining (Fig. 2). The intensity was focal weak
or moderate. None (0/5) of clear cell carcinomas showed pos-
itive staining. The benign mucinous and serous cystadeno-
mas were all negative. 
Mutational analysis by SSCP 
Mutational analysis was applied to all cases of carcinomas
and borderline tumors. No mutation was identified at exon
11. Two cases of borderline mucinous tumors and one case
of mucinous cystadenocarcinoma had mutation at exon 17
(Fig. 3, 4). In these cases, the immunohistochemistry also
shows focal positive staining at epithelial component. The
results are presented in Table 2. 
Correlation of c-kit immunohistochemical expression and
mutation with clinical parameters
In immunohistochemical results, two cases of c-kit positive
mucinous cystadenocarcinoma were stage Ic and II. One case
of serous cystadenocarcioma was stage IIIc with pelvic meta-
stasis but no recurrence. In exon 17 mutational analyses, one
patient with mucinous cystadenocarcinoma had stage Ic. 
DISCUSSION
The evidence of surface epithelial origin in ovarian tumors
is strongest for the serous, endometrioid, and clear cell sub-
types and substantial for mucinous tumors (13), and greater
than 95% of ovarian carcinomas originate from the surface
epithelium. According to the research of Parrott et al. (14),
KIT ligand and c-kit was detected in normal human ovarian
surface epithelium. Their research also demonstrated that
the expression of KIT ligand and receptor c-kit protein was
examined at borderline tumor, stage I & stage III ovarian
cancers. The intensity of immunohistochemical staining was
decreased in advanced tumors. Their observations support
the hypothesis that KIT ligand and c-kit may play an impor-
tant role in normal ovarian surface epithelium and progres-
sion of ovarian cancer. 
Based on this hypothesis, we performed c-kit immunohis-
tochemical stain on mucinous, serous and clear cell carcino-
mas including borderline tumors. The study about expres-
sion of c-kit in ovarian epithelial cancers has been investi-
gated previously, but the results vary considerably among
the groups. And, most of the studies were focused on immuno-
histochemical expression. Little is known about c-kit muta-
tional status and only a few studies have reported that no
mutation of KIT was found in serous ovarian carcinomas (15,
16). In the research of Tonary et al. (17), there was a decrease
or lack of KIT expression in advanced stage malignant ovar-
ian tumors. As the tumor types, serous carcinomas show 76%,
mucinous carcinomas 0%, endometrioid carcinomas 60%,
and clear cell carcinoma 75% positive c-kit expression in
immunohistochemistry. They also found that low malignant
potential tumors show higher expression than malignant
tumors. In contrast to this, Schmandt et al. (18) demonstrat-
ed that c-kit immunohistochemical staining was absent in
low grade tumors but was present in high-grade serous car-
cinomas. Also, c-kit expression was correlated with progres-
sion of disease after first-line chemotherapy and chemother-
apy resistance (19). Thus, there are many disparities between
groups with regard to expression of KIT in ovary. 
Imatinib mesylate, tyrosine kinase inhibitor has been
reported to be effective in cases of tumors with an exon 11-
activating KIT mutation. So, to determine the efficacy of
imatinib mesylate, we performed mutational analysis on
exon 11 and exon 17 of c-kit in ovarian surface epithelial
carcinomas. As the result, the positive rate of c-kit immuno-
histochemical stain was greater in mucinous tumors than
serous tumors. In mucinous tumors, borderline tumors showed
higher incidence than malignant one. The c-kit immunohis-
tochemical expression was not correlated with tumor stage
or histological grade. The mutation at exon 11 was not found
in any of our cases. However, mutation at exon 17 was pre-
sent at two cases of borderline mucinous tumors and one case
of mucinous cystadenocarcinoma with stage Ic. 
The results of our study suggest that ovarian surface epithe-
lial carcinomas show less frequent expression of KIT protein
in serous type and lack KIT-activating mutation in exon 11.
Although the immunohistochemistry for KIT protein show
positive expression in some ovarian tumors, the therapy with
imatinib mesylate may not be indicated because immuno-
histochemistry is not correspond to KIT-activating muta-
tion in exon 11. It is reasonable to predict that ovarian sur-
face epithelial tumors are unlikely to respond to imatinib
mesylate and the role of c-kit protooncogene in ovarian car-
cinogenesis is not be clearly verified.
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